Compare CDLX & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | ONCY |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.5M | 106.1M |
| IPO Year | 2018 | 1999 |
| Metric | CDLX | ONCY |
|---|---|---|
| Price | $1.03 | $0.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.25 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 769.7K | 669.1K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,175,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $0.33 |
| 52 Week High | $4.05 | $1.51 |
| Indicator | CDLX | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 48.10 |
| Support Level | $0.95 | $0.92 |
| Resistance Level | $1.10 | $1.06 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 25.00 | 64.65 |
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.